Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2023 Vol. 1 > No. 2 > 100028
Next Article Previous Article
COMMENTARY   Open Access     Cite

Universal chimeric antigen receptor-T cells: An opening era for T-cell malignancies

  • 1.

    Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

  • 2.

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan 430030, China

  • 3.

    National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

  • 4.

    Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

More Information
The Innovation Medicine  1(2),  https://doi.org/10.59717/j.xinn-med.2023.100028  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Sasu, B.J., Opiteck, G.J., Gopalakrishnan, S., et al. (2023). Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells. Mol. Ther. 31: 676−685. DOI: 10.1016/j.ymthe.2022.12.004.

    View in Article CrossRef Google Scholar Scopus

    [2] Jeong, Y.K., Song, B., and Bae, S. (2020). Current status and challenges of DNA base editing tools. Mol. Ther. 28: 1938−1952. DOI: 10.1016/j.ymthe.2020.07.021.

    View in Article CrossRef Google Scholar

    [3] Liu, J., Zhang, Y., Guo, R., et al. (2023). Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: Recent advances. Front. Immunol. 14: 1170968. DOI: 10.3389/fimmu.2023.1170968.

    View in Article CrossRef Google Scholar

    [4] Chiesa, R., Georgiadis, C., Syed, F., et al. (2023). Base-edited CAR7 T cells for relapsed T-Cell acute lymphoblastic leukemia. N. Engl. J. Med. 389 : 899-910. DOI: 10.1056/NEJMoa2300709.

    View in Article Google Scholar

    [5] Pan, J., Tan, Y., Wang, G., et al. (2021). Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. J Clin Oncol 39: 3340−3351. DOI: 10.1200/JCO.21.00389.

    View in Article CrossRef Google Scholar Scopus

    • Cited by

  • Cite this article:

    Wang J., Chen Y., Cao Y., et al., (2023). Universal chimeric antigen receptor-T cells: An opening era for T-cell malignancies. The Innovation Medicine 1(2), 100028. https://doi.org/10.59717/j.xinn-med.2023.100028
    Wang J., Chen Y., Cao Y., et al., (2023). Universal chimeric antigen receptor-T cells: An opening era for T-cell malignancies. The Innovation Medicine 1(2), 100028. https://doi.org/10.59717/j.xinn-med.2023.100028

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(4241) PDF downloads(1865)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.